Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
17
pubmed:dateCreated
1995-10-26
pubmed:abstractText
We describe severe and unexpected multisystem toxicity that occurred during a study of the antiviral nucleoside analogue fialuridine (1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-iodouracil, or FIAU) as therapy for chronic hepatitis B virus infection.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0028-4793
pubmed:author
pubmed:issnType
Print
pubmed:day
26
pubmed:volume
333
pubmed:owner
NLM
pubmed:authorsComplete
N
pubmed:pagination
1099-105
pubmed:dateRevised
2010-3-24
pubmed:meshHeading
pubmed-meshheading:7565947-Acidosis, Lactic, pubmed-meshheading:7565947-Adult, pubmed-meshheading:7565947-Alanine Transaminase, pubmed-meshheading:7565947-Antiviral Agents, pubmed-meshheading:7565947-Arabinofuranosyluracil, pubmed-meshheading:7565947-Chronic Disease, pubmed-meshheading:7565947-DNA, Mitochondrial, pubmed-meshheading:7565947-DNA, Viral, pubmed-meshheading:7565947-Drugs, Investigational, pubmed-meshheading:7565947-Female, pubmed-meshheading:7565947-Hepatitis B, pubmed-meshheading:7565947-Humans, pubmed-meshheading:7565947-Jaundice, pubmed-meshheading:7565947-Liver, pubmed-meshheading:7565947-Liver Failure, pubmed-meshheading:7565947-Liver Transplantation, pubmed-meshheading:7565947-Male, pubmed-meshheading:7565947-Middle Aged, pubmed-meshheading:7565947-Pancreatitis, pubmed-meshheading:7565947-Peripheral Nervous System Diseases
pubmed:year
1995
pubmed:articleTitle
Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B.
pubmed:affiliation
Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial, Clinical Trial, Phase II